Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Prinses Máxima Centrum Voorpagina
Nederlands
English
Voorpagina
Profielen
Onderzoeksgroepen
Uitrusting
Onderzoeksoutput
Prijzen
Activiteiten
Knipsels
Zoeken op expertise, naam of affiliatie
Rationale for using TNFα and chemotherapy in regional therapy of melanoma
F. Lejeune
, D. Liénard
,
A. Eggermont
, H. Schraffordt Koops
, F. Rosenkaimer
, J. Gérain
, J. Klaase
, B. Kroon
, J. Vanderveken
, P. Schmitz
Onderzoeksoutput
:
Bijdrage aan tijdschrift
›
Artikel
›
peer review
47
Citaten (Scopus)
Overzicht
Vingerafdruk
Vingerafdruk
Duik in de onderzoeksthema's van 'Rationale for using TNFα and chemotherapy in regional therapy of melanoma'. Samen vormen ze een unieke vingerafdruk.
Sorteer per
Gewicht
Alfabetische volgorde
Keyphrases
Chemotherapy
100%
Recombinant
100%
Melanoma
100%
Locoregional Therapy
100%
Tumor Necrosis Factoralpha
100%
Perfusion
50%
Melphalan
33%
Metastatic Stage
16%
Tumor Cells
16%
Antitumor Activity
16%
Maximum Tolerated Dose
16%
Human Tumor Xenograft
16%
Immunohistochemical Study
16%
Systemic Circulation
16%
High Dose
16%
Complete Response
16%
Tumor Endothelial Cells
16%
Intensive Care
16%
Synergism
16%
Lysis
16%
Closed-loop System
16%
Biochemotherapy
16%
Dose-ranging
16%
Dual Targeting
16%
Immunological Study
16%
Angiographic Study
16%
Medicine and Dentistry
Tumor Necrosis Factor
100%
Tumor Necrosis
100%
Chemotherapy
100%
Melanoma
100%
Limb
50%
Isolation Perfusion
50%
Melphalan
33%
Malignant Neoplasm
16%
Neoplasm
16%
Metastatic Carcinoma
16%
Tumor Cell
16%
Intensive Care
16%
Tumor Xenograft
16%
Endothelial Cell
16%
Antineoplastic Activity
16%
Drug Megadose
16%
Systemic Circulation
16%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Melanoma
100%
Tumor Necrosis Factor
100%
Tumor Necrosis
100%
Neoplasm
50%
Melphalan
33%
Malignant Neoplasm
16%
Antitumor Activity
16%
Maximum Tolerated Dose
16%
Synergism
16%
Systemic Circulation
16%